An Open Label, International, Multi-Center, Phase I/IIA Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed/Refractory Hodgkin Lymphoma, Mature T-Cell Lymphoma and Multiple Myeloma (RID Study)
Diseases and Conditions Researched
Hodgkin's Lymphoma; Multiple Myeloma; Non-Hodgkin's Lymphoma
What is the purpose of this trial?
- To establish DLTs and an MTD for the combination of romidepsin and lenalidomide for patients with lymphoma; and of romidepsin, lenalidomide and dexamethasone for patients with myeloma.
- To establish tolerability and feasibility at the recommended phase-II doses for the combination regimens.
- To establish initial evidence of efficacy in each of the three treatment groups according to histological diagnosis.
- To explore the immunological, histological and gene-expression correlates of disease response and drug toxicity.
Click here for detailed participation information for this trial.
|Sponsors:||Celgene Corporation; Yale Cancer Center|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.